Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
Background Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported. Case presentation We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months. Conclusion This case suggests new perspectives for the treatment of asbestosis and its systemic features..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
BMC musculoskeletal disorders - 16(2015), 1 vom: 14. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Niccoli, Laura [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Niccoli et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( |
|---|
| doi: |
10.1186/s12891-015-0602-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR028032837 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR028032837 | ||
| 003 | DE-627 | ||
| 005 | 20230519130546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12891-015-0602-6 |2 doi | |
| 035 | |a (DE-627)SPR028032837 | ||
| 035 | |a (SPR)s12891-015-0602-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Niccoli, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Niccoli et al. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( | ||
| 520 | |a Background Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported. Case presentation We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months. Conclusion This case suggests new perspectives for the treatment of asbestosis and its systemic features. | ||
| 650 | 4 | |a Asbestosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interleukin-1beta |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Autoimmunity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Canakinumab |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Cassarà, Emanuele |4 aut | |
| 700 | 1 | |a Kaloudi, Olga |4 aut | |
| 700 | 1 | |a Nannini, Carlotta |4 aut | |
| 700 | 1 | |a Romagnoli, Micaela |4 aut | |
| 700 | 1 | |a Cantini, Fabrizio |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC musculoskeletal disorders |d London : BioMed Central, 2000 |g 16(2015), 1 vom: 14. Juni |w (DE-627)SPR028003829 |w (DE-600)2041355-5 |x 1471-2474 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2015 |g number:1 |g day:14 |g month:06 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12891-015-0602-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2015 |e 1 |b 14 |c 06 | ||